<DOC>
<DOCNO>
EP-0001365
</DOCNO>
<TEXT>
<DATE>
19790404
</DATE>
<IPC-CLASSIFICATIONS>
C12N-7/00 A61K-39/12 <main>C12N-7/04</main> A61K-39/245 
</IPC-CLASSIFICATIONS>
<TITLE>
antigenic, immunogenic herpes virus subunit and process for preparing it.
</TITLE>
<APPLICANT>
merck & co incus<sep>merck & co. inc.<sep>merck &amp; co., inc.126, east lincoln avenue p.o. box 2000 rahway new jersey 07065-0900 us <sep>merck & co. inc.<sep>merck & co. inc. <sep>
</APPLICANT>
<INVENTOR>
larson vivian<sep>lehman ernest dale<sep>larson, vivian<sep>lehman, ernest dale<sep>larson, vivian362 park driveharleysville pennsylvania 19438us<sep>lehman, ernest dale229 hunter lanenorth wales pennsylvania 19454us<sep>larson, vivian<sep>lehman, ernest dale<sep>larson, vivian<sep>lehman, ernest dale  <sep>larson, vivian362 park driveharleysville pennsylvania 19438us<sep>lehman, ernest dale229 hunter lanenorth wales pennsylvania 19454us<sep>
</INVENTOR>
<ABSTRACT>
herpes virus subunit antigens suitable for vaccine use  are prepared by (1) treating virus-infected cells with a surfactant  and varying concentrations of salt to extract and solubilize  viral-directed glycoproteins, (2) fractionating the solubilized  material by chromatographic procedures to enrich the  viral-directed glycoproteins and to remove unwanted proteins  and nucleic acids, and (3) optionally treating the subunit  antigens with deoxyribonuclease and formaldehyde to assure  safety.  
</ABSTRACT>
</TEXT>
</DOC>
